81 related articles for article (PubMed ID: 25643776)
1. [Neoadjuvant Chemotherapy (NC) Response in Patients with Breast Cancer According to Immunohistochemical Intrinsic Subtypes (IHC)].
Ruvalcaba Limón E; Barreda Zelaya LE; García Orozco N; Morales Vásquez F; Bautista Piña V; Maffuz Aziz A; Rodríguez Cuevas S
Gac Med Mex; 2014 Dec; 150 Suppl 2():161-70. PubMed ID: 25643776
[TBL] [Abstract][Full Text] [Related]
2. Luminal B, Human Epidermal Growth Factor Receptor 2 (HER2/neu), and Triple-Negative Breast Cancers Associated With a Better Chemotherapy Response Than Luminal A Breast Cancers in Postneoadjuvant Settings.
Hashmi AA; Bukhari U; Najam J; Dowlah T; Ali AH; Diwan MA; Anjali F; Sham S; Zia S; Irfan M
Cureus; 2023 Jun; 15(6):e40066. PubMed ID: 37425505
[TBL] [Abstract][Full Text] [Related]
3. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
de Ronde JJ; Hannemann J; Halfwerk H; Mulder L; Straver ME; Vrancken Peeters MJ; Wesseling J; van de Vijver M; Wessels LF; Rodenhuis S
Breast Cancer Res Treat; 2010 Jan; 119(1):119-26. PubMed ID: 19669409
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
5. Tumor response to neoadjuvant chemotherapy in molecular breast cancer subtypes in Medellin, Colombia. Retrospective cohort study.
Restrepo-Mejía M; Guarín-García AM; Bonilla-Sepúlveda ÓA; Rincón-Medina M; Barrera-Arenas LM
Rev Colomb Obstet Ginecol; 2023 Jun; 74(2):143-152. PubMed ID: 37523685
[TBL] [Abstract][Full Text] [Related]
6. Relationship between intrinsic subtypes and tumor responses to neoadjuvant chemotherapy in patients with locally advanced breast cancer.
Ooe A; Takahara S; Sumiyoshi K; Yamamoto H; Kawai J; Shiba E
Breast Dis; 2012; 34(1):9-17. PubMed ID: 23507670
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
[TBL] [Abstract][Full Text] [Related]
8. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
9. Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.
Matsubara N; Mukai H; Fujii S; Wada N
Breast Cancer Res Treat; 2013 Jan; 137(1):203-12. PubMed ID: 23184081
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer subtype discrimination using standardized 4-IHC and digital image analysis.
Gándara-Cortes M; Vázquez-Boquete Á; Fernández-Rodríguez B; Viaño P; Ínsua D; Seoane-Seoane A; Gude F; Gallego R; Fraga M; Antúnez JR; Curiel T; Pérez-López E; García-Caballero T
Virchows Arch; 2018 Feb; 472(2):195-203. PubMed ID: 28825136
[TBL] [Abstract][Full Text] [Related]
12. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
von Minckwitz G; Untch M; Blohmer JU; Costa SD; Eidtmann H; Fasching PA; Gerber B; Eiermann W; Hilfrich J; Huober J; Jackisch C; Kaufmann M; Konecny GE; Denkert C; Nekljudova V; Mehta K; Loibl S
J Clin Oncol; 2012 May; 30(15):1796-804. PubMed ID: 22508812
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.
Duman BB; Afşar ÇU; Günaldi M; Sahin B; Kara IO; Erkisi M; Erçolak V
Asian Pac J Cancer Prev; 2012; 13(8):4119-23. PubMed ID: 23098527
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical profile and clinical-pathological variables in breast cancer.
Cintra JR; Teixeira MT; Diniz RW; Gonçalves Junior H; Florentino TM; Freitas GF; Oliveira LR; Neves MT; Pereira T; Guerra MR
Rev Assoc Med Bras (1992); 2012; 58(2):178-87. PubMed ID: 22569612
[TBL] [Abstract][Full Text] [Related]
15. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy.
Gómez R; Ossa CA; Montoya ME; Echeverri C; Ángel G; Ascuntar J; Borrero M; Gil M; Herrera S; Gutiérrez E; Herazo F; Jiménez A; Madrid J; Reyes PA; Zuluaga L; García H
Ecancermedicalscience; 2015; 9():562. PubMed ID: 26316883
[TBL] [Abstract][Full Text] [Related]
16. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of Breast Cancer Molecular Subtypes and Ki67 Expression as a Predictive Value for Pathological Complete Response following Neoadjuvant Chemotherapy: Experience from a Tertiary Care Center in Lebanon.
Atoui A; Bou Zerdan M; El Mahmoud A; Chamseddine N; Hamad L; Assi HI
Int J Breast Cancer; 2022; 2022():1218128. PubMed ID: 35190777
[TBL] [Abstract][Full Text] [Related]
18. Predictive role of molecular subtypes in response to neoadjuvant chemotherapy in breast cancer patients in Northeast China.
Lv M; Li B; Li Y; Mao X; Yao F; Jin F
Asian Pac J Cancer Prev; 2011; 12(9):2411-7. PubMed ID: 22296393
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging in breast cancer treated with neoadjuvant chemotherapy: radiologic-pathologic correlation of the response and disease-free survival depending on molecular subtype.
Cruz Ciria S; Jiménez Aragón F; García Mur C; Esteban Cuesta H; Gros Bañeres B
Radiologia; 2014; 56(6):524-32. PubMed ID: 23294850
[TBL] [Abstract][Full Text] [Related]
20. Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement.
Pereira A; Siegrist J; Lizarraga S; Pérez-Medina T
J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
